Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.48 |
| ▸ | ANPEP | P15144 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 4/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4925778 | 0.77 | HTR2A (0.45) | HTR2AANPEPKDM1AHRH1RET | |
| SCHEMBL3426562 | 0.71 | HTR2A (0.38) | HTR2AANPEPHRH1RETHTR2C | |
| SCHEMBL5751646 | 0.71 | HTR2A (0.38) | HTR2AHRH1HTR2C | |
| SCHEMBL3078945 | 0.71 | HTR2A (0.38) | HTR2AANPEPHRH1RETHTR2C | |
| SCHEMBL5749663 | 0.71 | HTR2A (0.38) | HTR2AANPEPKDM1AHRH1RET | |
| SCHEMBL6763552 | 0.71 | HTR2A (0.38) | HTR2AANPEPHRH1RETHTR2C | |
| SCHEMBL528662 | 0.71 | HTR2A (0.38) | HTR2AANPEPHRH1RETHTR2C | |
| SCHEMBL1030610 | 0.69 | ALDH1A1 (0.42) | HTR2AANPEPHRH1RETHTR2C | |
| SCHEMBL6632659 | 0.67 | PDPK1 (0.46) | HTR2AHRH1HTR2CSIGMAR1 | |
| SCHEMBL11312986 | 0.67 | PRCP (0.43) | HTR2AHRH1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317459-B1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | GYS1, GYS2, PYGL | HTR2A 3403/4885ANPEP 510/4885KDM1A 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.